All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NMD670
Therapeutic Area: Immunology Product Name: NMD670
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IRL201805
Therapeutic Area: Immunology Product Name: IRL201805
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Morningside Ventures
Deal Size: $53.4 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 21, 2020
Details:
Funding will accelerate Immune Regulation’s efforts to develop first-in-class drug product candidates that reset the immune system from a pro-inflammatory state to a balanced state, with the potential to achieve long term disease remission in autoimmune and allergic diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KZR-616
Therapeutic Area: Immunology Product Name: KZR-616
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
Results from the Phase 1b portion of the MISSION study demonstrating safety, tolerability and early efficacy signals of KZR-616 in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) were presented at the Pan-American Congress of Rheumatology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IRL201805
Therapeutic Area: Immunology Product Name: IRL201805
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
1805 is a first-in-class compound derived from the endogenous immuno-regulatory protein Binding Immunoglobulin Protein (BiP) and is in development to treat rheumatoid arthritis and other inflammatory and autoimmune diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: Alzumab
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
Details:
Across the first two dose cohorts itolizumab has been generally well tolerated to date, and five of seven patients achieved a complete response (CR) by Day 29.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ANX005
Therapeutic Area: Immunology Product Name: ANX005
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Redmile Group
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 01, 2020
Details:
This financing is intended to advance multiple product candidates in Annexon’s portfolio, including ANX005 and ANX007.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KZR-616
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2020
Details:
Overall, improvements were seen across 7 measures of disease activity, and 2 of 2 patients with lupus nephritis experienced a greater than 50% reduction in proteinuria. A positive safety and tolerability profile was observed with step-up dosing of KZR-616.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALPN-101
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
The posters are going to cover Study of ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KZR-616
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2020
Details:
Kezar anticipate delays in their previously anticipated clinical development and data release milestones for KZR-616. However, Phase 1b portion of their MISSION study will continue to receive data.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2020
Details:
The research, conducted in mouse models, demonstrates that blockade of the CD6-ALCAM pathway with anti-CD6 antibodies reduces incidence and severity of both GVHD and gastro-intestinal inflammation.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
